+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Liquid Biopsy Market Research Report by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4989607
  • Report
  • July 2021
  • Region: Global
  • 184 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Breast Cancer Liquid Biopsy Market will Grow to USD 840.93 Million by 2026, at a CAGR of 19.24%

FEATURED COMPANIES

  • Adaptive Biotechnologies
  • Biodesix, Inc.
  • Exosome Diagnostics, Inc.
  • Fluxion Biosciences, Inc.
  • Illumina, Inc
  • Myriad Genetics
  • MORE
The Global Breast Cancer Liquid Biopsy Market size was estimated at USD 292.45 Million in 2020 and expected to reach USD 347.75 Million in 2021, at a Compound Annual Growth Rate (CAGR) 19.24% to reach USD 840.93 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Breast Cancer Liquid Biopsy to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on End-User, the Breast Cancer Liquid Biopsy Market was studied across Hospitals & Physician Laboratories and Reference Laboratories.
  • Based on Biomarker, the Breast Cancer Liquid Biopsy Market was studied across Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), and Other Circulating Biomarkers.
  • Based on Region, the Breast Cancer Liquid Biopsy Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Liquid Biopsy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Liquid Biopsy Market, including Adaptive Biotechnologies, Bio-Rad Laboratories Inc, Biocept Inc, Biodesix, Biodesix, Inc., Epic Sciences, Exosome Diagnostics, Inc., F. Hoffmann-La Roche Ltd, FLUXION BIOSCIENCES, Fluxion Biosciences, Inc., GUARDANT HEALTH, INC, Guardant Health, Inc, Illumina, Inc, Isogen Life Science, Janssen Diagnostics LLC, Myriad Genetics, PapGene Inc, Pathway Genomics (OME Care), Qiagen N V, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Breast Cancer Liquid Biopsy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Liquid Biopsy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Liquid Biopsy Market?
4. What is the competitive strategic window for opportunities in the Global Breast Cancer Liquid Biopsy Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Liquid Biopsy Market?
6. What is the market share of the leading vendors in the Global Breast Cancer Liquid Biopsy Market?
7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Liquid Biopsy Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adaptive Biotechnologies
  • Biodesix, Inc.
  • Exosome Diagnostics, Inc.
  • Fluxion Biosciences, Inc.
  • Illumina, Inc
  • Myriad Genetics
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. End-User Outlook
3.4. Biomarker Outlook
3.5. Region Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of breast cancer
5.1.1.2. Increasing demand for non-invasive breast cancer treatment
5.1.1.3. Availability of funding for liquid biopsy R&D
5.1.2. Restraints
5.1.2.1. Stringent Regulatory Issues
5.1.2.2. High cost of breast cancer liquid biopsy
5.1.3. Opportunities
5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
5.1.4. Challenges
5.1.4.1. Poor Reimbursement Policies
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Breast Cancer Liquid Biopsy Market, by End-User
6.1. Introduction
6.2. Hospitals & Physician Laboratories
6.3. Reference Laboratories

7. Breast Cancer Liquid Biopsy Market, by Biomarker
7.1. Introduction
7.2. Cell-free DNA (cfDNA)
7.3. Circulating Tumor Cells (CTCs)
7.4. Extracellular Vesicles (EVs)
7.5. Other Circulating Biomarkers

8. Americas Breast Cancer Liquid Biopsy Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Adaptive Biotechnologies
12.2. Bio-Rad Laboratories Inc
12.3. Biocept Inc
12.4. Biodesix
12.5. Biodesix, Inc.
12.6. Epic Sciences
12.7. Exosome Diagnostics, Inc.
12.8. F. Hoffmann-La Roche Ltd
12.9. FLUXION BIOSCIENCES
12.10. Fluxion Biosciences, Inc.
12.11. GUARDANT HEALTH, INC
12.12. Guardant Health, Inc
12.13. Illumina, Inc
12.14. Isogen Life Science
12.15. Janssen Diagnostics LLC
12.16. Myriad Genetics
12.17. PapGene Inc
12.18. Pathway Genomics (OME Care)
12.19. Qiagen N V
12.20. Thermo Fisher Scientific Inc.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2020 (USD MILLION)
FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2020 (USD MILLION)
FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2026
FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2020 VS 2026 (%)
FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2020 VS 2026 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2026
FIGURE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA (CFDNA), 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA (CFDNA), BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTCS), 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTCS), BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES (EVS), 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES (EVS), BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OTHER CIRCULATING BIOMARKERS, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OTHER CIRCULATING BIOMARKERS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 26. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 27. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 28. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 29. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 30. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 31. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 32. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 33. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 34. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 35. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 36. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 37. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 38. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 39. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 40. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 41. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 42. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 43. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 44. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: FPNV POSITIONING MATRIX
FIGURE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 57. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA (CFDNA), BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTCS), BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES (EVS), BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OTHER CIRCULATING BIOMARKERS, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 13. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 14. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 15. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 16. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 21. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 22. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: SCORES
TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: BUSINESS STRATEGY
TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: PRODUCT SATISFACTION
TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: RANKING
TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: MERGER & ACQUISITION
TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: INVESTMENT & FUNDING
TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Adaptive Biotechnologies
  • Bio-Rad Laboratories Inc
  • Biocept Inc
  • Biodesix
  • Biodesix, Inc.
  • Epic Sciences
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd
  • FLUXION BIOSCIENCES
  • Fluxion Biosciences, Inc.
  • GUARDANT HEALTH, INC
  • Guardant Health, Inc
  • Illumina, Inc
  • Isogen Life Science
  • Janssen Diagnostics LLC
  • Myriad Genetics
  • PapGene Inc
  • Pathway Genomics (OME Care)
  • Qiagen N V
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll